Table 3.

Edratide common adverse events (AEs)—incidence presented by preferred/high-level term and dose and sorted by the risk ratio of pooled Edratide doses versus placebo

	Pooled Edratide doses (N=253)	0.5 mg Edratide (N=84)	1 mg Edratide (N=87)	2.5 mg Edratide (N=82)	Placebo (N=87)
Preferred term	Percentage of subjects	Percentage of subjects	Percentage of subjects	Percentage of subjects	Percentage of subjects	Risk ratio of Pooled Edratide versus Placebo
Oedema peripheral	4.3	6.0	5.7	1.2	1.1	3.8
Liver function analyses	3.6	3.6	3.4	3.7	1.1	3.3
Weight increased	3.2	1.2	5.7	2.4	1.1	2.8
Hypertension (HTN)/labile HTN/blood pressure (BP) Increased/hypertensive crisis/hypertensive encephalopathy	7.5	9.5	2.3	12.2	3.4	2.2
Fungal vaginal infection	2.4	4.8	1.1	1.2	1.1	2.2
International normalised ratio (INR)/INR increased	2.4	2.4	4.6	–	1.1	2.2
Hypoaesthesia	2.4	2.4	3.4	1.2	1.1	2.1
Urticarias	2.0	3.6	2.3	–	1.1	1.8
Back pain	7.9	7.1	5.7	11.0	4.6	1.7
Diarrhoea	5.9	3.6	6.9	7.3	3.4	1.7
Dizziness	4.0	2.4	5.7	3.7	2.3	1.7
Depression	2.0	1.2	1.1	3.7	1.1	1.7
Dyspnoea	2.0	1.2	3.4	1.2	1.1	1.7
Palpitations	2.0	2.4	2.3	1.2	1.1	1.7
Nausea and vomiting symptoms	11.9	14.3	9.2	12.2	8.0	1.5
Injection site reactions	17.8	17.9	16.1	19.5	12.6	1.4
Insomnia	3.2	4.8	2.3	2.4	2.3	1.4
Seasonal allergy	1.6	1.2	–	3.7	1.1	1.4
Arthralgia/musculoskeletal pain	5.9	8.4	4.6	4.9	4.6	1.3
Cough	4.3	3.6	6.9	2.4	4.6	0.9
Dermatitis and eczema	2.0	–	1.1	4.9	2.3	0.9
Herpes viral infections	4.3	2.4	8.0	2.4	0	0
Vertigo/vertigo positional	4.0	4.8	4.6	2.4	0	0
Migraine	3.2	1.2	6.9	1.2	0	0
Tachycardia/tachycardia paroxysmal	3.2	3.6	4.6	1.2	0	0
Pharyngitis	2.4	3.6	1.1	2.4	0	0
Sciatica	2.0	1.2	3.4	1.2	−0	0
Dysgeusia	2.0	0	–	6.1	0	0
Abdominal pain upper	2.0	0	3.4	2.4	0	0